Genotype-phenotype correlations between gba mutations and parkinson disease risk and onsetsymbol

Neurology

Volumn 70, Issue 24, 2008, Pages 2277-2283

  Gan Or, Z ^a   Giladi, N ^a   Rozovski, U ^a   Shifrin, C ^a   Rosner, S ^a   Gurevich, T ^a   Bar Shira, A ^a   Orr Urtreger, A ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCOSIDASE; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; GLUCOSYLCERAMIDASE; LEUCINE RICH REPEAT KINASE 2;

ADULT; AGED; ARTICLE; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HETEROZYGOTE; HUMAN; JEW; MALE; MIDDLE AGED; MUTATION; ONSET AGE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; RANDOMIZATION; RISK FACTOR; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; GAUCHER DISEASE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE PHENOTYPE CORRELATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SYMPTOMATOLOGY;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; BETA-GLUCOSIDASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HUMANS; JEWS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; RANDOM ALLOCATION; RISK FACTORS;

EID: 46049112735     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000304039.11891.29     Document Type: Article

References (37)

1. Beutler E, Grabowski G. Gaucher disease. In: Scriver CR, Beaudet AL, Valle D, Sly WS, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2001:3635-3668.
2. Beutler E, Gelbart T, Scott CR. Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis 2005;35:355-364.
3. Neudorfer O, Giladi N, Elstein D, et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 1996;89:691-694.
4. Machaczka M, Rucinska M, Skotnicki AB, Jurczak W. Parkinson's syndrome preceding clinical manifestation of Gaucher's disease. Am J Hematol 1999;61:216-217.
5. Tayebi N, Callahan M, Madike V, et al. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 2001;73:313-321.
6. Tayebi N, Walker J, Stubblefield B, et al. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 2003;79:104-109.
7. Varkonyi J, Rosenbaum H, Baumann N, et al. Gaucher disease associated with parkinsonism: four further case reports. Am J Med Genet A 2003;116:348-351.
8. Bembi B, Zambito MS, Sidransky E, et al. Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology 2003;61:99-101.
9. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E. Parkinsonism among Gaucher disease carriers. J Med Genet 2004;41:937-940.
10. Itokawa K, Tamura N, Kawai N, Shimazu K, Ishii K. Parkinsonism in type I Gaucher's disease. Intern Med 2006;45:1165-1167.
11. Kono S, Shirakawa K, Ouchi Y, et al. Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier. J Neurol Sci 2007;252:181-184.
12. Halperin A, Elstein D, Zimran A. Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol Dis 2006;36:426-428.
13. Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E. Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 2004;81:70-73.
14. Eblan MJ, Walker JM, Sidransky E. The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 352:728-731, 2005; author reply 728-731.
15. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004;351:1972-1977.
16. Zimran A, Neudorfer O, Elstein D. The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 352:728-731, 2005; author reply 728-731.
17. Clark LN, Nicolai A, Afridi S, et al. Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Mov Disord 2005;20:100-103.
18. Sato C, Morgan A, Lang AE, et al. Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord 2005;20:367-370.
19. Eblan MJ, Nguyen J, Ziegler SG, et al. Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela. Mov Disord 2006;21:282-283.
20. Ziegler SG, Eblan MJ, Gutti U, et al. Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab 2007;91:195-200.
21. Tan EK, Tong J, Fook-Chong S, et al. Glucocerebrosidase mutations and risk of Parkinson disease in chinese patients. Arch Neurol 2007;64:1056-1058.
22. Toft M, Pielsticker L, Ross OA, Aasly JO, Farrer MJ. Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology 2006;66:415-417.
23. Wu YR, Chen CM, Chao CY, et al. Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J Neurol Neurosurg Psychiatry 2007;78:977-979.
24. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
25. Orr-Urtreger A, Shifrin C, Rozovski U, et al. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson's disease: is there a gender effect? Neurology 2007;69:1595-1602.
26. Horowitz M, Pasmanik-Chor M, Borochowitz Z, et al. Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population. Hum Mutat 1998;12:240-244.
27. Anca M, Paleacu D, Shabtai H, Giladi N. Cross-sectional study of the prevalence of Parkinson's disease in the Kibbutz movement in Israel. Neuroepidemiology 2002;21:50-55.
28. Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000;160:2835-2843.
29. Sidransky E. Gaucher disease and parkinsonism. Mol Genet Metab 2005;84:302-304.
30. Hruska KS, Goker-Alpan O, Sidransky E. Gaucher disease and the synucleinopathies. J Biomed Biotechnol 2006;2006:78549.
31. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 2006;7:306-318.
32. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006;354:424-425.
33. Clark LN, Wang Y, Karlins E, et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 2006;67:1786-1791.
34. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39:889-909.
35. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003;302:819-822.
36. Cookson MR. The biochemistry of Parkinson's disease. Annu Rev Biochem 2005;74:29-52.
37. Tan EK, Skipper LM. Pathogenic mutations in Parkinson disease. Hum Mutat 2007;28:641-653.